Objective: To report and evaluate a new Vision Impairment Screening Assessment (VISA) tool intended for use by the stroke team to improve identification of visual impairment in stroke survivors.
BACKGROUND
Visual impairment following stroke is common and estimated to affect two thirds of all stroke survivors 1 . There is currently no standardised protocol for screening or referral and, for these patients, a considerable proportion of patients who have visual problems go unrecognised, thus receiving no advice or management 2 . There are various visual treatment options that can have a beneficial effect on vision and to general rehabilitation [3] [4] [5] . Visual impairment can have a substantial impact on quality of life including loss of confidence, impaired mobility, inability to judge distances and increased risk of falls 3 . There is a known link between poor vision, quality of life and depression in older persons 4 6 . For these reasons it is important that patients with visual impairment are identified by the stroke multidisciplinary team (MDT) and appropriate referral made for specialist vision assessment. It is equally important that the effects of visual impairment on functional ability are established and information is provided regarding the use of residual vision to facilitate general rehabilitation. These issues have been recognised as research priorities in the James Lind Alliance sight loss prioritisation process in which screening and assessment of stroke survivors for visual problems is listed as a top ten priority for research 7 .
The aim of this study was to develop and evaluate a Vision Impairment Screening Assessment (VISA) tool using simple established assessments of visual function coupled with detailed instructions and tested against a reference of a full vision assessment, plus to assess the agreement of results between the screening and vision assessments.
METHODS

Development
The VISA screening tool was developed following consultation with an expert panel consisting of:
stroke-specialist clinical orthoptists, stroke research orthoptists, stroke survivors with visual impairment, stroke-specialist occupational therapists and neuro-ophthalmology. The panel considered results of recent stroke/vision research studies in which multiple measures of visual function were made 2 8 . They identified the consistent vision measures across the common visual impairments occurring following stroke -those of impaired central vision, eye movement, visual field and visual attention.
Stroke survivors provided specific input on potential burden of these assessments to individuals, particularly when undertaken in the early acute stage post stroke onset. Following this panel discussion, a draft screening tool was circulated along with detailed instructions compiled for each of the screening assessments. An iterative process was followed in which the panel provided written feedback on the first and subsequent drafts of the screening tool. 
Pilot validation
A prospective case cohort comparative design was used for the pilot validation clinical study.
Individuals were suitable for inclusion if they were 18 years of age or older, had clinical diagnosis of stroke as defined by World Health Organisation 9 , had the ability to agree to vision screening using verbal or non-verbal indications of agreement, did not have severe cognitive impairment preventing screening and did not decline vision screening. Our inclusion criteria were intended to be pragmatic and inclusive of as many stroke survivors as possible.
Recruitment took place across three hospitals in which an orthoptist routinely screened each patient admitted to the stroke unit (as per national guidelines: Royal College of Physicians Intercollegiate Stroke Guidelines and British & Irish Orthoptic Society extended guidelines for stroke practice) to determine whether they have visual impairment 10 11 . This study collected results from these routine orthoptic vision assessments for those individuals who were also screened within 24 hours for visual impairment using the VISA screening tool. The screening tool was used by medical students and orthoptists, and always compared to a second independent vision assessment (n=5 orthoptists/ophthalmologists). Medical students (n=2) were chosen as screeners to represent completely naïve individuals in conducting vision screening assessments. Orthoptists (n=4) were also chosen as screeners in this pilot stage of validation to serve as a quality check of the screening tool's ability to accurate assess various aspects of visual impairment.
Each patient was also assessed with comprehensive vision assessment comprising: case history, visual acuity, ocular alignment and movement, visual field and visual perception. This assessment was undertaken within 24 hours (typically the same day) of the screening assessment -to minimise effect of potential recovery. The order of screening and vision assessments varied to avoid the effects of fatigue and bias towards either the screen or vision assessments. The screener and orthoptist were blinded to each other's assessments to prevent bias of assessment.
Results were taken in numerical format from the referral forms completed by both the screener and orthoptist. The primary outcome measure was presence or absence of visual impairment (defined as low vision <0.2, visual field loss, eye movement abnormality, visual perceptual abnormality) and recorded as a binary measure: Yes/No for presence/absence of visual impairment.
Statistical methodology and sample size
The full vision assessment was taken as the reference standard. Kappa values assessing chanceeliminated agreement were calculated between the screening and vision assessment results. Level of sensitivity was estimated as the proportion of patients with visual impairment that are correctly identified by the screener, and the corresponding 95% confidence interval was calculated.
Additionally, we estimated the level of specificity as the proportion of patients without visual impairment that are correctly identified by the screener, and the corresponding 95% confidence interval. Further, we calculated the positive and negative predictive values for screening assessment.
As this was a pilot validation study, we sought to include a minimum sample size of 100 subjects.
This sample size is typically used for diagnostic accuracy studies, which we considered appropriate even though this was a study of screening detection rather than diagnostic accuracy 12 .
Process evaluation
Process evaluation for acceptability of the VISA tool was through a combination of feedback sheets and one-to-one interviews with screeners. Interviews and feedback sheets were transcribed and all identifying features removed. Qualitative data analysis was undertaken as an on-going iterative process. All transcripts were systematically coded manually. A thematic approach to analysis of the qualitative data was adopted. Codes were grouped for similar content and these groups defined the key emerging themes. A modified grounded theory approach was undertaken in which themes were revised iteratively as further interviews and analysis progressed.
RESULTS
Completion rate
One hundred and sixteen stroke patients (67% female, mean age 68.9 years) received both a VISA screening assessment and a reference vision assessment, over a four-month period. Two medical students conducted 62 of the screening assessments and 54 were screened by a team of four The screening assessment was fully completed by 89 patients, with the remaining 28 missing one or more elements (n=4 near vision, n=6 distance vision, n=3 convergence, n=9 visual fields, n=28 visual inattention). The vision assessment was fully completed by 77 patients, with the remaining 40 missing one or more elements (n=3 near vision, n=9 distance vision, n=18 convergence, n=9 visual fields, n=23 visual inattention). Reasons for missing data were captured and typically related to patient inability to complete sections of vision assessments because of impaired cognitive ability or fatigue.
Referral agreement
The agreement of whether to make a referral to specialist eye services based on the results of the screening tool versus those from full vision assessment had a Kappa value of 0.736 (95% CI 0.602 -0.870).
In this pilot evaluation of the VISA screening tool, sensitivity of 90.24% and specificity of 85.29%
were found. The positive and negative predictive values were 93.67% and 78.36% respectively.
These calculations are outlined in Table 1 . and found not to be present by the vision assessment.
Test component agreement
The agreement for the individual components between the screening tool and vision assessments are outlined in Table 2 . The highest levels of agreement were produced for distance visual acuity (0.785) and visual fields (0.741). The lowest levels of agreement were produced for ocular motility (0.120) and visual inattention (0.361). Low agreement for ocular motility related to high false negatives where 21 cases (3 with multiple conditions) were not detected -these comprised of: nine defects of vertical movement (including four age-related restrictions, one 4 th cranial nerve palsy and one V-pattern), eight cases of nystagmus (including four end-point nystagmus), five restrictions of horizontal eye movements and four cases of reduced convergence. The low agreement with visual inattention related to false positive referrals because of failure of the patient to complete this section due to impaired cognitive ability or fatigue -rather than true presence of visual inattention. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y 8
Naïve versus non-naïve screeners
The agreement on whether to make a referral to specialist eye services based on results of the screening tool versus those from full vision assessment was stronger when made by a non-naïve screener (Table 3) . A higher rate of false positive and false negatives were found when the screener was naïve to vision testing (eleven false referrals for naïve vs two for non-naïve screeners). The agreement on whether to make a referral to specialist eye services between the screening tool and a vision assessment had a Kappa value of 0.736 (95% CI 0.602 -0.870).
When used by a naïve screener the VISA tool has a sensitivity of 82.93% and specificity of 80.95%.
When used by non-naïve screeners the sensitivity the tool has a sensitivity of 97.56% and specificity of 92.31%. 
Process evaluation
Information from feedback sheets and detailed notes from interviews were compiled and grouped for type of feedback. Group themes included instruction feedback, section feedback and referral feedback.
Instruction feedback: Screeners asked for brief instruction reminders at the top of screening assessments, for example, position test chart at 3 metres from the patient, cover each eye in turn,
etc. This served to act as a quick reminder for the correct procedure for that particular section of the screening tool. Clarifications were requested for the main instruction training section such that potential ambiguity was removed.
Section feedback: In the first version, each screening section was coupled to the detailed assessment instructions. Screeners requested that all detailed instructions be merged into one training 'manual' section with the screening assessments separate. As screeners became more familiar with the tool, they used the screening assessments on their own and kept the detailed instructions elsewhere (mainly for reference) which meant there was less paperwork to be carried to the bedside assessment. 
DISCUSSION
In this study, we present the VISA screening tool which encompasses screening of key visual results were interpreted as borderline fail by screeners. Visual inattention was the last section to be completed in the screening assessment so, as a result, likely to be most susceptible to the effects of fatigue and impaired cognition. Guidance on completing the screening assessment was therefore amended such that the more interactive components of the screening assessment were advised to be completed first in such cases plus a repeat second screen where indicated.
Process evaluation aided further refinement of the screening tool and, in particular, training elements and referral guidance to add quick tips and reminders, and to remove ambiguity. Vision screening of stroke survivors by orthoptists using validated assessments has been shown to provide 13 . Such Orthoptic input has been reported to help prevent misdiagnosis, provide quick access to treatment of visual problems and improve response to general rehabilitation 4 14 . Orthoptists are a member of the core acute stroke MDT (10) . Despite consistent findings that inclusion of vision services within the MDT is highly beneficial, such visual assessment is not common and services are inconsistent throughout the UK. One survey showed that 45% of stroke services provided no formal vision assessment for stroke patients 15 . A further survey of practice identified that only 7% of stroke units had a policy relating to vision assessment and management 16 . Both surveys showed lack of standardisation for vision assessment and treatment for stroke survivors. The National Stroke Strategy argues that vision and visual perceptual difficulties are components requiring multi-faceted stroke specific rehabilitation and support 17 . The
Royal College of Physicians recommend that every patient with stroke should have a practical assessment of vision and examination of the visual field 10 .
Problems exist with referral accuracy from the MDT where there is suspected visual difficulty. It is reported that where referral by the MDT was based on the identification of ocular signs only, there was reduced sensitivity (42%) and specificity (52%). Referral accuracy improved when visual symptoms were taken into account. Concerns were raised regarding potential failure to refer those patients unable to report their visual symptoms due to communication and cognitive deficits 3 .
Inconsistencies between identification of ocular signs on assessment by the MDT and final ocular diagnosis have also been documented in an audit of stroke referrals for vision assessment. Fifty-six percent of visual diagnoses made prior to formal eye assessment were incorrect with amended diagnoses being made following visual assessment by the orthoptic/ophthalmic team 18 . Our VISA screen at this early pilot stage appears to increase the accuracy of screening by increasing the ability and detect ocular signs separate to reporting of vision symptoms.
In each of the above studies, the MDT used a screening form on which they specified whether they noted any obvious visual signs such as nystagmus, strabismus or ptosis and whether the patient complained of visual symptoms such as double vision or reading difficulty. They did not, however, undertake any measurement of visual function. A further study evaluated Cardiff cards as a screening measure to identify low levels of vision 19 . A comparative study of qualitative methods of visual field assessment reported the difficulty in screening for visual field impairment in acute stages of stroke follow-up 20 . However, the authors recognised that confrontation is widely regarded as the most viable screening option for bedside visual field assessment (19) . Visual inattention is the most common visual perceptual disorder and there are various screening assessments in use for its 21 .
Limitations: The VISA screening tool was used by a combination of medial students and orthoptists whilst full vision assessment was provided by a team of orthoptists and ophthalmologists. Arguably, results wold be more meaningful if all screening assessments were completed by staff naïve to any vision assessment. Because this was a pilot validation study, we chose to include screening assessments from both medical students with no vision assessment experience, and orthoptists who were experienced in vision assessment. Medical students represented completely naïve individuals in conducting vision screening assessments. However, orthoptists were chosen as screeners in this pilot stage of validation to serve as a quality check of the screening tool's ability to accurate assess various aspects of visual impairment. Our process evaluation for acceptability of the screening assessment involved feedback and interviewers with screeners only. We acknowledge this limitation and an important next step is to obtain views of stroke survivors on the acceptability of the screening assessment and its perceived value to them. A further limitation is that the screening assessment was not timed consistently for duration. Completion of the screening assessment was approximately 10 minutes in the small number that could be assessed but this cannot be taken as a representative screen duration. The screening duration is an important consideration when adding to busy acute stroke services and will be captured fully in the next stage of validation.
Our next stage of development is a full clinical validation of the VISA tool where all screening assessments are completed by naïve screeners versus reference comprehensive vision assessment.
CONCLUSIONS
This early validation of the VISA screening tool shows promise in improving detection accuracy with potential to lead to more prompt referral with fewer false positives and negatives. The benefits are that it may support increased speed of access to appropriate treatment of visual impairment and potential to preserve and make best use of remaining visual function for patients. Identification of visual impairment and implementation of early interventions and compensatory options has impact to overall rehabilitation, quality of life and activities of daily living with potential cost savings to the NHS by enhancing rehabilitation and supporting early discharge. Establishment of an effective vision screening tool is likely to be highly transferable to other vulnerable groups in other hospital inpatient areas, residential care settings or community multidisciplinary team assessments. Screening test negative n=37
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Baseline demographic and clinical characteristics of participants #5 Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.
DEVELOPMENT
This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.
More information can be found on http://www.equator-network.org/reporting-guidelines/stard. 
Strengths and limitations of this study
• Iterative development process for the screening tool.
• Prospective clinical pilot validation process.
• Comparison made between naïve and non-naïve screeners.
• Acceptability of the screening assessment to stroke survivors was not captured.
• The duration of the screening assessment was not captured. poor vision, quality of life and depression in older persons (4, 6) . For these reasons it is important that patients with visual impairment are identified by the stroke multidisciplinary team (MDT) and appropriate referral made for specialist vision assessment. It is equally important that the effects of visual impairment on functional ability are established and information is provided regarding the use of residual vision to facilitate general rehabilitation. These issues have been recognised as research priorities in the James Lind Alliance sight loss prioritisation process, in which screening and assessment of stroke survivors for visual problems is listed as a top ten priority for research (7).
The overall aim of this study was to develop and evaluate a Vision Impairment Screening Assessment (VISA) tool using simple established assessments of visual function coupled with detailed instructions. Our objectives were to test the VISA screen against a reference of a specialist vision assessment to determine sensitivity, specificity, predictive values and inter-rater agreement of results between the VISA screen and specialist vision assessments. A final objective was to evaluate user views on the acceptability of use of the VISA screening tool.
Methods
Development
The VISA screening tool was developed following consultation with an expert panel consisting of: Stroke survivors provided specific input on potential burden of these assessments to individuals, particularly when undertaken in the early acute stage post stroke onset. Following this panel discussion, a draft screening tool was circulated along with detailed instructions compiled for each of 
Pilot validation
Individuals were suitable for inclusion if they were 18 years of age or older, had clinical diagnosis of stroke as defined by World Health Organisation (9), had the ability to agree to vision screening using verbal or non-verbal indications of agreement, did not have severe cognitive impairment preventing screening and did not decline vision screening. Our inclusion criteria were intended to be pragmatic and inclusive of as many stroke survivors as possible. The clinical study was undertaken in accordance with the Tenets of Helsinki with NHS research ethical approval.
For the purpose of this study, vision screening was undertaken with the VISA screening tool and screening was defined as the assessment of stroke survivors for the presence of reduced visual function against pre-set abnormality criteria. Specialist visual assessment was defined as the vision assessment undertaken by eye-trained clinicians (orthoptists and ophthalmologists) in which Each stroke survivor underwent two vision assessments: the routine orthoptic specialist vision assessment (n=5 orthoptists/ophthalmologists) and the VISA screening assessment. The VISA screen was completed by medical students and orthoptists. Medical students (n=2) were chosen as screeners to represent completely naïve individuals in conducting vision screening assessments.
Orthoptists (n=4) were also chosen as screeners in this pilot stage of validation to serve as a quality check of the screening tool's ability to accurate assess various aspects of visual impairment.
. Routine specialist vision assessment comprised detailed diagnostic assessments of case history, visual acuity, ocular alignment and movement, visual field and visual perception. This assessment was undertaken within 24 hours (typically the same day) of the VISA screen -to minimise effect of potential recovery.
The order of the VISA screening and specialist vision assessments varied to avoid the effects of fatigue and bias towards either the screen or vision assessments. The screener and orthoptist were blinded to each other's assessments to prevent bias of assessment. The within-assessment order of testing varied for the specialist assessment. However, the order of testing within the VISA screen followed a set order of 1) case history, 2) visual acuity, 3) eye position, 4) visual field and 5) visual inattention assessments.
Statistical methodology and sample size
Results were taken in numerical format from the referral forms completed by both the screener and orthoptist. The specialist vision assessment was taken as the reference standard.
The primary outcome measure was presence or absence of visual impairment (defined as low vision Level of sensitivity was estimated as the proportion of patients with visual impairment that are correctly identified by the screener, and the corresponding 95% confidence interval was calculated.
Level of specificity was estimated as the proportion of patients without visual impairment that are correctly identified by the screener, and the corresponding 95% confidence interval. Further, we calculated the positive and negative predictive values for the VISA screen.
This sample size is typically used for diagnostic accuracy studies, which we considered appropriate even though this was a study of screening detection rather than diagnostic accuracy (12) .
Process evaluation
Process evaluation for acceptability of the VISA tool during the clinical study was through a combination of feedback sheets and one-to-one interviews with screeners. Feedback sheets could be returned at any time during the study to report any issues with testing alongside obtaining clinician views based on their use of the VISA tool. Feedback sheets asked the following: 6. Should any other tests be added in?
7. How long does it take you to do the screen?
Other comments?
These questions were also asked during individual interviews. Interviews were conducted by the lead author (FR).
Interviews and feedback sheets were transcribed verbatim and all identifying features removed.
Qualitative data analysis was undertaken as an on-going iterative process. All transcripts were systematically coded manually. A thematic approach to analysis of the qualitative data was adopted.
Transcripts were coded by sentence or section and the code descriptors were derived directly from the text. A thematic approach to analysis of the qualitative data was adopted. Codes were grouped for similar content and these groups defined the key emerging themes. A modified grounded theory approach was undertaken in which themes were revised iteratively as further interviews and analysis progressed.
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Results
Completion rate
One hundred and sixteen stroke patients received both a VISA screening assessment and a reference vision assessment, over four months (Dec 2015-Mar 2016). Two medical students conducted 62 of the VISA screens and 54 were screened by a team of four orthoptists. Independent specialist vision assessment was conducted by a team of four orthoptists and one ophthalmologist.
The VISA screen was fully completed by 89 patients, with the remaining 28 missing one or more elements (n=4 near vision, n=6 distance vision, n=3 convergence, n=9 visual fields, n=28 visual inattention). The specialist vision assessment was fully completed by 77 patients, with the remaining 40 missing one or more elements (n=3 near vision, n=9 distance vision, n=18 convergence, n=9 visual fields, n=23 visual inattention). Reasons for missing data were captured and typically related to patient inability to complete sections of vision assessments because of impaired cognitive ability or fatigue. All patients were included even if there was missing data -missing data did not automatically result in failure for that section, thereby requiring referral. Reasons behind the failure to complete sections were always taken into consideration.
Referral agreement
The agreement of whether to make a referral to specialist eye services based on the results of the VISA screening tool versus those from specialist vision assessment had a Kappa value of 0.736 (95% CI 0.602 -0.870).
These calculations are outlined in Table 1 .
Page 7 of 18
For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml BMJ Open   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Agreement was found for 103 participants (29 had no visual impairment, 74 required referral because of failed screening), outlined in Figure 1 . The VISA screen produced eight false negative and five false positive results. Of the false negative results, three had ocular motility problems, three had reduced distance vision, one had reduced near vision and one did not have visual fields tested during screening. For false positive results, two with visual inattention, two with visual field loss and one with both visual inattention and visual field loss, were detected by screening and found not to be present by the vision assessment.
Test component agreement
The agreement for the individual components between the VISA screen and specialist vision assessments are outlined in Table 2 . The highest levels of agreement were produced for distance The low agreement with visual inattention related to false positive referrals because of failure of the patient to complete this section due to impaired cognitive ability or fatigue -rather than true presence of visual inattention. 
Naïve versus non-naïve screeners
The agreement on whether to make a referral to specialist eye services based on results of the VISA screening tool versus those from specialist vision assessment was stronger when made by a nonnaïve screener (Table 3) . A higher rate of false positive and false negatives were found when the screener was naïve to vision testing (eleven false referrals for naïve vs two for non-naïve screeners).
The agreement on whether to make a referral to specialist eye services between the VISA screening tool and a specialist vision assessment had a Kappa value of 0.736 (95% CI 0.602 -0.870).
When used by a naïve screener the VISA screen has a sensitivity of 82.93% and specificity of 80.95%.
When used by non-naïve screeners the sensitivity the VISA screen has a sensitivity of 97.56% and specificity of 92.31%. 
Process evaluation
Instruction feedback: Screeners asked for brief instruction reminders at the top of VISA screening assessments, for example, position test chart at 3 metres from the patient, cover each eye in turn,
Section feedback: In the first version, each screening section was coupled to the detailed assessment instructions. Screeners requested that all detailed instructions be merged into one training 'manual' section with the screening assessments separate. As screeners became more familiar with the tool, they used the VISA screens on their own and kept the detailed instructions elsewhere (mainly for reference) which meant there was less paperwork to be carried to the bedside assessment.
Referral feedback: Most feedback concerned patients who were borderline on whether to refer for specialist vision assessment or not. For example, where the patient had borderline visual acuity responses -perhaps because glasses were not available -but all other visual function assessments passed the VISA screen. In other cases, the patient lacked sufficient cognitive or communication abilities rendering some VISA screens 'unsure' or incomplete. Detailed referral guidelines were compiled to guide the referral process with minimum guidance being to repeat the VISA screen 1-2 days later for borderline cases. This aimed to reduce the levels of false referrals.
Discussion
In this study, we present the VISA screening tool which encompasses screening of key visual 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Process evaluation aided further refinement of the VISA screening tool and, in particular, training elements and referral guidance to add quick tips and reminders, and to remove ambiguity. Vision screening of stroke survivors by orthoptists using validated assessments has been shown to provide accurate identification of visual impairment and is easily undertaken on the stroke unit with further follow-up arranged in eye clinics as required (13) . Such Orthoptic input has been reported to help prevent misdiagnosis, provide quick access to treatment of visual problems and improve response to general rehabilitation (4, 14) . Orthoptists are a member of the core acute stroke MDT (10) . Despite consistent findings that inclusion of vision services within the MDT is highly beneficial, such visual assessment is not common and services are inconsistent throughout the UK. One survey showed that 45% of stroke services provided no formal vision assessment for stroke patients (15) . A further survey of practice identified that only 7% of stroke units had a policy relating to vision assessment and management (16) . Both surveys showed lack of standardisation for vision assessment and treatment for stroke survivors. The National Stroke Strategy argues that vision and visual perceptual difficulties are components requiring multi-faceted stroke specific rehabilitation and support (17).
The Royal College of Physicians recommend that every patient with stroke should have a practical assessment of vision and examination of the visual field (10).
Problems exist with referral accuracy from the MDT where there is suspected visual difficulty. It is reported that where referral by the MDT was based on the identification of ocular signs only, there Inconsistencies between identification of ocular signs on assessment by the MDT and final ocular diagnosis have also been documented in an audit of stroke referrals for vision assessment (18) . Fiftysix percent of visual diagnoses made prior to formal eye assessment were incorrect with amended diagnoses being made following visual assessment by the orthoptic/ophthalmic team (18) . Our VISA screen at this early pilot stage appears to increase the accuracy of screening by increasing the ability to detect ocular signs separate to reporting of vision symptoms.
In each of the above studies, the MDT used a screening form on which they specified whether they noted any obvious visual signs such as nystagmus, strabismus or ptosis and whether the patient complained of visual symptoms such as double vision or reading difficulty. They did not, however, undertake any measurement of visual function. A further study evaluated Cardiff cards as a screening measure to identify low levels of vision (19) . A comparative study of qualitative methods of visual field assessment reported the difficulty in screening for visual field impairment in acute stages of stroke follow-up (20) . However, the authors recognised that confrontation is widely regarded as the most viable screening option for bedside visual field assessment (19) . Visual inattention is the most common visual perceptual disorder and there are various screening assessments in use for its detection but which do not extend to other facets of visual impairment (21) . In each of these studies, individual assessments of one aspect of visual function are considered.
However, an overall visual screening assessment for stroke survivors is currently not available for use by MDTs in the absence of assessment by eye care professionals (21) .
Limitations: The VISA screening tool was used by a combination of medial students and orthoptists whilst specialist vision assessment was provided by a team of orthoptists and ophthalmologists.
Arguably, results wold be more meaningful if all VISA screens were completed by staff naïve to any vision assessment. Because this was a pilot validation study, we chose to include VISA screens from both medical students with no vision assessment experience, and orthoptists who were experienced in vision assessment. Medical students represented completely naïve individuals in conducting vision screening assessments. However, orthoptists were chosen as screeners in this pilot stage of validation to serve as a quality check of the screening tool's ability to accurate assess various aspects of visual impairment. Our process evaluation for acceptability of the VISA screen involved feedback and interviewers with screeners only. We acknowledge this limitation and an important next step is to obtain views of stroke survivors on the acceptability of the VISA screen and its perceived value to them. A further limitation is that the VISA screen was not timed consistently for duration. 
Conclusions
This early validation of the VISA screening tool shows promise in improving detection accuracy for clinicians involved in stroke care who are not specialists in vision problems and lack formal eye training, with potential to lead to more prompt referral with fewer false positives and negatives.
Clinicians reported acceptability of the VISA screening tool for is use in screening for presence of vision problems in stroke survivors. Referral sensitivity of 90% and specificity of 80% were found for the VISA screening with strong inter-rater agreement for referral between VISA screening and specialist vision assessments.
The benefits are that the VISA screening tool may support increased speed of access to appropriate treatment of visual impairment and potential to preserve and make best use of remaining visual function for patients. Identification of visual impairment and implementation of early interventions and compensatory options has impact to overall rehabilitation, quality of life and activities of daily living with potential cost savings to the NHS by enhancing rehabilitation and supporting early discharge. Establishment of an effective vision screening tool is likely to be highly transferable to other vulnerable groups in other hospital in-patient areas, residential care settings or community multidisciplinary team assessments.
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EXPLANATION
A diagnostic accuracy study evaluates the ability of one or more medical tests to correctly classify study participants as having a target condition. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.
The test whose accuracy is evaluated is called index test. A study can evaluate the accuracy of one or more index tests.
Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the reference standard. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.
If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the sensitivity of the index test (the proportion of participants with the target condition who have a positive index test), and its specificity (the proportion without the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or "2x2" table), several other accuracy statistics can be estimated, such as the positive and negative predictive values of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical precision of the measurements.
If the index test results can take more than two values, categorization of test results as positive or negative requires a test positivity cut-off. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The area under the ROC curve informs in a single numerical value about the overall diagnostic accuracy of the index test.
The intended use of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The clinical role of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.
Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.
DEVELOPMENT
More information can be found on http://www.equator-network.org/reporting-guidelines/stard.
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